Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Steps forward for cancer precision medicine

Nature Reviews Drug Discovery volume 17, pages 1–2 (2018)Cite this article

Subjects

Abstract

The availability of targeted anticancer drugs and the relative affordability of genomic analyses has led to a growing expectation among patients with cancer that they can receive personalized treatment based on the genomic signature of their tumour. Here, we discuss some of the challenges and steps needed to bring such approaches into routine practice.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Salgado, R. et al. Societal challenges of precision medicine: bringing order to chaos. Eur. J. Cancer 84, 325–334 (2017).

    Article  PubMed  Google Scholar 

  2. San Miguel, L. & Hulstaert, F. The importance of test accuracy in economic evaluations of companion diagnostics. J. Comp. Eff. Res. 4, 569–577 (2015).

    Article  PubMed  Google Scholar 

  3. Borrebaeck, C. A. Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer. Nat. Rev. Cancer 17, 199–204 (2017).

    Article  CAS  PubMed  Google Scholar 

  4. National Institutes of Health. NIH news releases. NIH https://www.nih.gov/news-events/news-releases/nih-partners-11-leading-biopharmaceutical-companies-accelerate-development-new-cancer-immunotherapy-strategies-more-patients, (2017).

Download references

Acknowledgements

Medical writing assistance was provided by Jim Heighway PhD, Cancer Communications and Consultancy Ltd, Knutsford, UK and was funded by the EORTC. The IBCD conference was made possible due to the generous support from Amgen (Europe) GmbH; AstraZeneca LP; Boehringer Ingelheim Pharma GmbH & Co. KG; Bristol-Myers Squibb; Celgene International II Sàrl; Région de Bruxelles-Capitale (Innoviris); Janssen Research & Development; LLC, KEOSYS Medical Imaging, Lilly USA, LLC; Pfizer Pharma GmbH; F. Hoffmann-La Roche Ltd; Millennium Pharmaceuticals, Inc. and Transgene SA. Roberto Salgado was supported by the Breast Cancer Research Foundation, New York, USA. (BCRF) (BCRF-16-182).

Author information

Authors and Affiliations

  1. Department of Pathology, Gasthuiszusters Antwerpen, Antwerp, Belgium

    Roberto Salgado

  2. Breast Cancer Translational Research Laboratory, Jules Bordet Institute, Brussels, Belgium

    Roberto Salgado

  3. Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia

    Roberto Salgado

  4. Biorepositories and Biospecimen Research Branch; Cancer Therapy Evaluation Program; DCTD and Investigational Drug Branch; DCTD; NCI, NIH,

    Helen Moore, Tracy Lively, Shakun Malik, Jeffrey A. Moscow & Tawnya McKee

  5. Division of Cancer Treatment and Diagnosis (DCTD), Bethesda, Maryland, USA

    Helen Moore, Tracy Lively, Shakun Malik, Jeffrey A. Moscow & Tawnya McKee

  6. Erasmus MC Cancer Institute and Cancer Genomics Netherlands, Erasmus University Medical Center, Rotterdam, The Netherlands

    John W. M. Martens

  7. Wellcome Trust Sanger Institute, Cambridge, UK

    Ultan McDermott

  8. INSERM, University Paris-Sud, Univerisity Paris Saclay, Villejuif, France

    Stefan Michiels

  9. University Hospital Gasthuisberg, Leuven, Belgium

    Sabine Tejpar

  10. EORTC Headquarters, Brussels, 1200, Belgium

    Denis Lacombe

Authors
  1. Roberto Salgado
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Helen Moore
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John W. M. Martens
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tracy Lively
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shakun Malik
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ultan McDermott
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Stefan Michiels
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jeffrey A. Moscow
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Sabine Tejpar
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Tawnya McKee
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Denis Lacombe
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the IBCD-Faculty

Corresponding author

Correspondence to Denis Lacombe.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary information box 1

IBCD meeting speakers and affiliations (PDF 59 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Salgado, R., Moore, H., Martens, J. et al. Steps forward for cancer precision medicine. Nat Rev Drug Discov 17, 1–2 (2018). https://doi.org/10.1038/nrd.2017.218

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd.2017.218

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research